Clinical trials: QL1706
Locally Advanced Rectal Cancer (LARC), 5-12cm to Anal Verge
Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal…
- Trial name
- IT-CABLE (NCT07769853)
- Testing
- Iparomlimab and Tuvonralimab（QL-1706）combined with Chemotherapy and Bevacizumab
- Volunteers
- 56 people
- Sponsor
- Zhejiang University
Lung Adenocarcinoma
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
The goal of this Phase II clinical trial (The PHOENIX Study) is to evaluate if the combination of QL1706 (Iparomlimab and Tuvonralimab), bevacizumab, and chemotherapy can treat patients with TKI-refractory, driver-gene positive…
- Trial name
- PHOENIX (NCT07416058)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Guangdong Association of Clinical Trials
NSCLC, NSCLC (Non-small Cell Lung Cancer)
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
The primary objective of this study is to evaluate whether neoadjuvant SBRT as an immunomodulator in combination with apalolimab and toripalimab (QL1706) plus chemotherapy improves the pathological complete response (pCR) rate in…
- Trial name
- NCT07286942
- Testing
- apalolimab and toripalimab (QL1706)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4).
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
- Trial name
- NCT07372079
- Testing
- QL1706 combined with Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Platinum-resistant Recurrent Ovarian Cancer
A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT06509971
- Testing
- QL1706
- Volunteers
- 39 people
- Sponsor
- West China Second University Hospital
Lung Cancer
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in PD-L1 negative, locally advanced or metastatic…
- Trial name
- NCT05690945
- Testing
- QL1706, Tilesizumab
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Locally Advanced Cervical Carcinoma
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
This study aims to compare the efficacy and safety of "neoadjuvant immunotherapy combined with chemotherapy followed by immunotherapy combined with radiotherapy during the radiotherapy period" versus "standard concurrent…
- Trial name
- NCT07613567
- Testing
- standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Fujian Cancer Hospital
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
- Trial name
- QUEEN-Dream (NCT06404736)
- Testing
- Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Intermediate Trophoblastic Tumor
Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors
This clinical trial aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706), a dual-targeting immunotherapy (anti-PD-1/CTLA-4), in patients with intermediate trophoblastic tumors (ITT).
- Trial name
- NCT06941766
- Testing
- QL1706, Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
QL1706, ESCC
Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma.
- Conditions
- QL1706, ESCC, First-line Therapy
- Trial name
- NCT07533305
- Testing
- QL1706 plus nab-paclitaxel and cisplatin
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Hepatocellular Carcinoma (HCC)
SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
SBRT combined with dual PD-1/CTLA-4 blockade (iparomlimab and tuvonralimab, QL1706) and bevacizumab may provide complementary local and systemic antitumor activity in hepatocellular carcinoma (HCC).
- Trial name
- NCT07882056
- Testing
- Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University Cancer Hospital & Institute
Uterine Cervical Neoplasms, Locally Advanced
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Purpose: To evaluate the efficacy and safety of neoadjuvant treatment with iparomlimab and tuvonralimab (QL1706), a dual PD1and CTLA4 bispecific antibody, in combination with paclitaxel and either cisplatin or carboplatin (TP/TC…
- Trial name
- QUARTZ-CC (NCT07646301)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer With Liver Metastases
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.
- Trial name
- NCT06787183
- Testing
- Short course radiotherapy, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Penile Cancer
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
This phase II clinical study aims to evaluate the efficacy and safety of QL1706 in combination with lenvatinib in patients with previously treated advanced or metastatic penile squamous cell carcinoma.
- Trial name
- NCT07384416
- Testing
- QL1706 + Lenvatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Melanoma (Skin) Stage IV
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.
- Trial name
- Cryo-IA-Check (NCT07847359)
- Testing
- Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
TNBC, Triple Negative Breast Cancer
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC
- Trial name
- NCT06786026
- Testing
- bevacizumab, QL1706, Nab paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Biliary Tract Cancer (BTC)
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
This study will evaluate the efficacy and safety of cryoablation combined with QL1706 (iparomlimab/tuvonralimab) plus lenvatinib in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.
- Trial name
- CASTLE-ZS-04 (NCT07829874)
- Testing
- QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib, Cryoablation
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Fudan University
Bone and Soft Tissue Tumors
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period.
- Trial name
- NCT06939855
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Colorectal Carcinoma
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
This is an open-label, muticenter phase II study to evaluate the efficacy and safety of QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment of unresectable advanced or metastatic CRC.
- Trial name
- NCT05799820
- Testing
- QL1706, Bevacizumab, Oxaliplatin injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.